Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05269667 · ClinicalTrials.gov registry record · Phase 4
A Study In Neuromyelitis Optica Spectrum Disorder (NMOSD) With Satralizumab As An Intervention
A Phase 4 study, sponsored by Hoffmann-La Roche.
- Terminated
- Registry status
- Phase 4
- Development phase
- 4
- Enrollment target
NCT05269667 is a Phase 4 study that was terminated before completion, run by Hoffmann-La Roche. The registered enrollment target is 4 participants.
The verdict
NCT05269667, a Phase 4 study, was terminated before completion, sponsored by Hoffmann-La Roche.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 4 participants
- Enrollment target
Study Summary
Objective of the trial is to describe the efficacy and safety of satralizumab in patients with aquaporin-4 (AQP4) antibody seropositive NMOSD, either treatment naive or inadequate responders to previous treatment with rituximab (RTX) (or its biosimilar)
Interventions
- DRUG Satralizumab 120 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2022-08-02 |
| Est. Completion | 2023-10-26 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05269667
The ClinicalTrials.gov registry entry for NCT05269667 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Satralizumab 120 mg is the first listed.
NCT05269667 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05269667 about?
NCT05269667 is a clinical study titled "A Study In Neuromyelitis Optica Spectrum Disorder (NMOSD) With Satralizumab As An Intervention". Objective of the trial is to describe the efficacy and safety of satralizumab in patients with aquaporin-4 (AQP4) antibody seropositive NMOSD, either treatment naive or inadequate responders to previous treatment with rituximab (RTX) (or its biosimilar)
What is the current status of trial NCT05269667?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 4 participants. The study started on 2022-08-02. Estimated completion is 2023-10-26.
What interventions are being tested in trial NCT05269667?
The interventions under investigation include: Satralizumab 120 mg (DRUG).
Who is sponsoring clinical trial NCT05269667?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.